Free Delivery on orders over £29*

Masivet Tablets for Dogs

Masivet Tablets for Dogs
50mg Tablets » Pot of 30

  • 50mg Tablets » Pot of 30 £54.99
  • 150mg Tablets » Pot of 30 £119.99

Selection of 2 products from

£54.99 to £119.99

Description

If you live in the United States then it is still possible to buy Kinavet (licensed as Masivet in the UK) from VioVet.

We can accept a prescription from a US veterinary surgeon under a USDA permit obtained by VioVet. We have a template and description of the prescription process on our website here. We would need your vet to date, sign and stamp the prescription, which must also include pet details, product name, strength and dosage. We would recommend that you scan/photograph and then email your completed prescription from your vet to us on [email protected] or upload a file directly via your account on our website.

Orders must be placed by the owner of the dog being treated - we cannot supply veterinary surgeries with Masivet under any circumstances due to FDA / USDA regulations. We also require a specific written order from a licensed veterinarian stating that the animal should receive the unapproved product and provide a justification for the use of the unapproved drug. We also need an explanation as to why Masivet must be prescribed instead of an alternative medication.

We strongly recommend that you look into import regulations affecting you before placing an order. Royal Mail parcels are not routinely checked by customs but any regulations are applied by customs if they inspect a parcel. We will include all relevant documentation as required by our USDA Import Permit for Masivet with every order to smooth the importation process however the FDA may charge a $22.00 Adminsitration Fee for clearance of the documentation. This will be payable, if requested, to the UPS driver on delivery and is a Federal charge not a VioVet or UPS charge. Please be aware that Royal Mail Air Mail is an untracked service. We can offer delivery with UPS, which offers a tracking service and a quicker estimated delivery time, often under one week. The option for shipping with UPS will be available on orders only containing Masivet.

We can only send a maximum of a three month supply per animal per order. You will be contacted if your order exceeds this and your order will be amended to the appropriate quantity.

Orders can be placed on our website and payment can be made by card, PayPal or direct bank transfer (2.5% fee for for PayPal). Unfortunately we are unable to quote in US dollars- your card provider will be able to tell you the conversion rate they are currently using and will automatically take the correct amount for the payment.

If you would like any further information then email us at [email protected] and we'll do our best to help.

Masivet (licensed as Kinavet in the USA) is supplied as a tablet for use against a certain type of cancer affecting dogs. Masivet is regarded as safe enough to be used at home, and is given as a tablet once daily. It acts against mast cell tumours, by inhibiting cell division, therefore preventing further development of the tumours. Not all dogs respond, but the results can be very helpful for others. Close veterinary supervision is recommended at all times and Masivet is prescription only.

What is Masivet?


Masivet contains masitinib, which belongs to a class of medicines having an anticancer action. It is available as round, orange tablets (50 and 150 mg).

What is Masivet used for?

Masivet is used to treat dogs with mast-cell tumours (a type of cancer). It is used for tumourswhich are severe in character (grade 2 or 3) and which cannot be removed with surgery. It isonly used if the presence of a mutated form of the receptor protein c-kit in the tumours hasbeen confirmed before the start of treatment.
The tablets are given by mouth, once a day. The dose depends on the weight of the dog beingtreated.. The duration of treatment depends on the dog’s response to treatment.

How does Masivet work?

The active substance in Masivet, masitinib, is aprotein-tyrosine kinase inhibitor. This meansthat it blocks some specific enzymes known astyrosine kinases. These enzymes can be foundin some receptors on the surface of cells, including the c-kit receptor. Some types of mast-celltumour are linked to a mutation that causes excessive action of c-kit and stimulates the mastcells to divide uncontrollably. By blocking these receptors, Masivet might help to control celldivision, preventing further development of the tumours with this particular mutation.

How has Masivet been studied?

A number of studies with Masivet were carried out either in laboratory dogs or in animalpatients at veterinary practises in Europe and in the USA. The main study compared theeffectiveness of Masivet at the recommended dose of 12.5 mg per kilogramme bodyweightonce a day with placebo (a dummy treatment). The study included dogs of various breeds andboth sexes with mast-cell tumours that had come back after surgery or could not be removedwith surgery. The study population included dogs whose tumours contained mutated ornormal (‘wild-type’) c-kit receptors.


What is the risk associated with Masivet?


The most common side effects with Masivet are gastrointestinal reactions (diarrhoea andvomiting) and hair loss. These reactions are usually mild to moderate and temporary, last forup to four weeks. Dogs under Masivet treatment should be regularly monitored for side effectsby the veterinarian (at least monthly). In case of side effects, the veterinarian might decide tolower the dose of Masivet or to discontinue treatment.
Masivet must not be used in dogs with certain kinds of liver or kidney problems, or anaemia (low red blood cell counts) or neutropenia (low white blood cell counts). It must not be used in dogs less than six months of age or less than 4kg in weight, or bitches that are pregnant or lactating. It should not be used in dogs that may be hypersensitive (allergic) to masitinib orany of the other ingredients. For a full list of all side-effects reported with Masivet, see the Package Leaflet.
Four to six weeks after starting the treatment with Masivet, the veterinarian should check ifthe treatment is likely to be successful.

What are the precautions for the person who gives the medicine or comes into contact with theanimal?

The tablets must be administered whole and should not be divided, broken or ground up. If broken tablets, or the vomit, urine or faeces of a treated dog comes into contact with the skinor eyes, rinse immediately with plenty of water. Children should not have close contact with treated dogs, or their faeces or vomit. If Masivet is taken accidentally, seek medical advice immediately and show the Package Leaflet or the label to the doctor. Do not eat, drink or smoke while treating a dog. For more information, see the Package Leaflet.


Why has Masivet been approved?

The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that thebenefits of Masivet exceed the risks for the treatment of non-resectable mast cell tumours(grade 2 or 3) that have a confirmed mutated c-kit tyrosine kinase receptor and recommended that Masivet be given a marketing authorisation. The benefit-risk balance may be found inmodule 6 of this EPAR.

Other information about Masivet

The European Commission granted a marketing authorisation valid throughout the European Union, for Masivet to AB Science S.A. on 17 November 2008. Information on the prescriptionstatus of this product may be found on the label/outer package. Because this disease is a life threatening condition and the overall number ofdogs affected is expected to be low, the CVMP guidelines on “Minor-Use-Minor-Species (MUMS) data requirements” were applied when assessing the dossier.

This summary was last updated on May 2009.

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm (Collections only)
  • Email: [email protected]

All prices include VAT where applicable.

Medication Datasheets

150mg Tablets » Pot of 30

Apoquel film-coated tablets for dogs

Presentation

Apoquel tablets contain 3.6, 5.4 or 16 mg oclacitinib (as oclacitinib maleate). Each tablet is marked with “AQ” on one side, with “S”, “M” or “L” on the other side referring to the tablet strengths.

Uses

Indicated for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs.

Dosage and administration

For oral use.

Dosage and treatment schedule

The recommended initial dose is 0.4 to 0.6 mg oclacitinib/kg bodyweight, administered orally, twice daily for up to 14 days.

For maintenance therapy, the same dose (0.4 to 0.6 mg oclacitinib/kg bodyweight) should then be administered only once a day. The requirement for long-term maintenance therapy should be based on an individual benefit-risk assessment.

Apoquel can be administered with or without food.

The dosing table below shows the number of tablets required. The tablets are breakable along the score line.

Contra-indications, warnings, etc

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs less than 12 months of age or less than 3 kg bodyweight.

Do not use in dogs with evidence of immune suppression, such as hyperadrenocorticism, or with evidence of progressive malignant neoplasia as the active substance has not been evaluated in these cases.

The safety of Apoquel during pregnancy, lactation or in dogs intended for breeding has not been established, so its use is not recommended.

Oclacitinib modulates the immune system and may increase susceptibility to infection and exacerbate neoplastic conditions. Dogs receiving APOQUEL tablets should therefore be monitored periodically with complete blood counts and serum biochemistry when on long-term treatment.

When treating pruritus associated with allergic dermatitis with oclacitinib, investigate and treat any underlying causes (e.g. flea allergic dermatitis, contact dermatitis, food hypersensitivity). Furthermore, in cases of allergic dermatitis and atopic dermatitis, it is recommended to investigate and treat complicating factors, such as bacterial, fungal or parasitic infections/infestations (e.g. flea and mange).

The common adverse reactions seen up to day 16 of the field trials are listed in the following table:

After day 16, the following have been observed:

The frequency of adverse reactions is defined using the following convention:

Treatment related clinical pathology changes were restricted to an increase in mean serum cholesterol and a decrease in mean leukocyte count, however, all mean values remained within the laboratory reference range. The decrease in mean leukocyte count observed in oclacitinib-treated dogs was not progressive, and affected all white blood cell counts (neutrophil, eosinophil and monocyte counts) except lymphocyte counts. Neither of these clinical pathology changes appeared clinically significant.In a laboratory study, the development of papillomas was noted in a number of dogs.

No drug interactions were observed in field studies where oclacitinib was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials and anti-inflammatories.

The impact of oclacitinib administration on vaccination with modified live vaccines, canine parvovirus (CPV), canine distemper virus (CDV) and canine parainfluenza (CPI) and inactivated rabies vaccine (RV), on 16 week old vaccine naïve puppies has been studied. An adequate immune response (serology) to CDV and CPV vaccination was achieved when puppies were administered oclacitinib at 1.8 mg/kg bodyweight twice daily for 84 days. However, the findings of this study indicated a reduction in serological response to vaccination with CPI and RV in puppies being treated with oclacitinib compared to untreated controls. The clinical relevance of these observed effects for animals vaccinated while being administered oclacitinib (in accordance with the recommended dosing regimen) is unclear.

Oclacitinib tablets were administered at 1x, 3x and 5x to healthy, one year old Beagle dogs twice daily for 6 weeks followed by once daily for 20 weeks.

Clinical observations that were considered likely to be related to oclacitinib treatment included: alopecia (local), papilloma, dermatitis, erythema, abrasions and scabbing/crusts, interdigital "cysts", and oedema of the paws. Dermatitis lesions were mostly secondary to the development of interdigital furunculosis on one or more paws during the study, with the number and frequency of observations increased with increasing dose. Lymphadenopathy of peripheral nodes was noted in all groups, increasing in frequency with increased dose, and was frequently associated with interdigital furunculosis. Papilloma was considered treatment related, but not dose related.

There is no specific antidote and in case of signs of overdose the dog should be treated symptomatically.

User warnings

Wash hands after administration.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the doctor.

Pharmaceutical precautions

Store below 25°C.

Any remaining half tablet should be placed back in the opened blister and stored in the original cardboard carton or in the HDPE bottle (for a maximum of 3 days).

Do not use after the expiry date which is stated on the blister or carton.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Keep out of the sight and reach of children.

For animal treatment only.

Legal category

Packaging quantities

Supplied in blister strips (each strip containing 10 film-coated tablets) or HDPE plastic bottles. Pack sizes of 20, 50 or 100 tablets. Not all pack sizes may be marketed.

Further information

Oclacitinib is a Janus kinase (JAK) inhibitor. It can inhibit the function of a variety of cytokines dependent on JAK enzyme activity. For oclacitinib, the target cytokines are those that are proinflammatory or have a role in allergic responses/pruritis.

Following oral administration in dogs, oclacitinib maleate is rapidly and well absorbed, with a time to peak plasma concentration (tmax) of less than 1 hour. The absolute bioavailability of oclacitinib maleate was 89%.

Total body oclacitinib clearance from plasma was low; 316 ml/h/kg bodyweight (5.3 ml/min/kg bodyweight), and the apparent volume of distribution at steady-state was 942 ml/kg bodyweight. Following intravenous and oral administration, the half-lives were similar at 3.5 and 4.1 hours respectively. Oclacitinib exhibits low protein binding.

Overall the major clearance route is metabolism, with minor contributions from renal and biliary elimination. Inhibition of canine cytochrome P450s is minimal. Therefore, the risk of metabolic drug-drug interactions due to oclacitinib inhibition is very low. No accumulation was observed in the blood of dogs treated for 6 months with oclacitinib.

Marketing Authorisation Number

EU/2/13/154/001-018

50mg Tablets » Pot of 30

Apoquel film-coated tablets for dogs

Presentation

Apoquel tablets contain 3.6, 5.4 or 16 mg oclacitinib (as oclacitinib maleate). Each tablet is marked with “AQ” on one side, with “S”, “M” or “L” on the other side referring to the tablet strengths.

Uses

Indicated for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs.

Dosage and administration

For oral use.

Dosage and treatment schedule

The recommended initial dose is 0.4 to 0.6 mg oclacitinib/kg bodyweight, administered orally, twice daily for up to 14 days.

For maintenance therapy, the same dose (0.4 to 0.6 mg oclacitinib/kg bodyweight) should then be administered only once a day. The requirement for long-term maintenance therapy should be based on an individual benefit-risk assessment.

Apoquel can be administered with or without food.

The dosing table below shows the number of tablets required. The tablets are breakable along the score line.

Contra-indications, warnings, etc

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs less than 12 months of age or less than 3 kg bodyweight.

Do not use in dogs with evidence of immune suppression, such as hyperadrenocorticism, or with evidence of progressive malignant neoplasia as the active substance has not been evaluated in these cases.

The safety of Apoquel during pregnancy, lactation or in dogs intended for breeding has not been established, so its use is not recommended.

Oclacitinib modulates the immune system and may increase susceptibility to infection and exacerbate neoplastic conditions. Dogs receiving APOQUEL tablets should therefore be monitored periodically with complete blood counts and serum biochemistry when on long-term treatment.

When treating pruritus associated with allergic dermatitis with oclacitinib, investigate and treat any underlying causes (e.g. flea allergic dermatitis, contact dermatitis, food hypersensitivity). Furthermore, in cases of allergic dermatitis and atopic dermatitis, it is recommended to investigate and treat complicating factors, such as bacterial, fungal or parasitic infections/infestations (e.g. flea and mange).

The common adverse reactions seen up to day 16 of the field trials are listed in the following table:

After day 16, the following have been observed:

The frequency of adverse reactions is defined using the following convention:

Treatment related clinical pathology changes were restricted to an increase in mean serum cholesterol and a decrease in mean leukocyte count, however, all mean values remained within the laboratory reference range. The decrease in mean leukocyte count observed in oclacitinib-treated dogs was not progressive, and affected all white blood cell counts (neutrophil, eosinophil and monocyte counts) except lymphocyte counts. Neither of these clinical pathology changes appeared clinically significant.In a laboratory study, the development of papillomas was noted in a number of dogs.

No drug interactions were observed in field studies where oclacitinib was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials and anti-inflammatories.

The impact of oclacitinib administration on vaccination with modified live vaccines, canine parvovirus (CPV), canine distemper virus (CDV) and canine parainfluenza (CPI) and inactivated rabies vaccine (RV), on 16 week old vaccine naïve puppies has been studied. An adequate immune response (serology) to CDV and CPV vaccination was achieved when puppies were administered oclacitinib at 1.8 mg/kg bodyweight twice daily for 84 days. However, the findings of this study indicated a reduction in serological response to vaccination with CPI and RV in puppies being treated with oclacitinib compared to untreated controls. The clinical relevance of these observed effects for animals vaccinated while being administered oclacitinib (in accordance with the recommended dosing regimen) is unclear.

Oclacitinib tablets were administered at 1x, 3x and 5x to healthy, one year old Beagle dogs twice daily for 6 weeks followed by once daily for 20 weeks.

Clinical observations that were considered likely to be related to oclacitinib treatment included: alopecia (local), papilloma, dermatitis, erythema, abrasions and scabbing/crusts, interdigital "cysts", and oedema of the paws. Dermatitis lesions were mostly secondary to the development of interdigital furunculosis on one or more paws during the study, with the number and frequency of observations increased with increasing dose. Lymphadenopathy of peripheral nodes was noted in all groups, increasing in frequency with increased dose, and was frequently associated with interdigital furunculosis. Papilloma was considered treatment related, but not dose related.

There is no specific antidote and in case of signs of overdose the dog should be treated symptomatically.

User warnings

Wash hands after administration.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the doctor.

Pharmaceutical precautions

Store below 25°C.

Any remaining half tablet should be placed back in the opened blister and stored in the original cardboard carton or in the HDPE bottle (for a maximum of 3 days).

Do not use after the expiry date which is stated on the blister or carton.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Keep out of the sight and reach of children.

For animal treatment only.

Legal category

Packaging quantities

Supplied in blister strips (each strip containing 10 film-coated tablets) or HDPE plastic bottles. Pack sizes of 20, 50 or 100 tablets. Not all pack sizes may be marketed.

Further information

Oclacitinib is a Janus kinase (JAK) inhibitor. It can inhibit the function of a variety of cytokines dependent on JAK enzyme activity. For oclacitinib, the target cytokines are those that are proinflammatory or have a role in allergic responses/pruritis.

Following oral administration in dogs, oclacitinib maleate is rapidly and well absorbed, with a time to peak plasma concentration (tmax) of less than 1 hour. The absolute bioavailability of oclacitinib maleate was 89%.

Total body oclacitinib clearance from plasma was low; 316 ml/h/kg bodyweight (5.3 ml/min/kg bodyweight), and the apparent volume of distribution at steady-state was 942 ml/kg bodyweight. Following intravenous and oral administration, the half-lives were similar at 3.5 and 4.1 hours respectively. Oclacitinib exhibits low protein binding.

Overall the major clearance route is metabolism, with minor contributions from renal and biliary elimination. Inhibition of canine cytochrome P450s is minimal. Therefore, the risk of metabolic drug-drug interactions due to oclacitinib inhibition is very low. No accumulation was observed in the blood of dogs treated for 6 months with oclacitinib.

Marketing Authorisation Number

EU/2/13/154/001-018

Delivery Information

How quickly do you deliver?

Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.

What do you charge for delivery?

For UK delivery, we charge the following:

Order Total Weight Delivery
£0-£28.99 Under 2kg £2.99
2kg+ £4.99
£29-£38.99 Under 2kg Free
2kg+ £4.99
£39+ Under 2kg Free
2kg+ Free

Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.

For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.

We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of £10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.

Delivery of aerosols

Due to air freight restrictions aerosols cannot ever be sent abroad by Royal Mail. We appreciate your understanding.

Delivery of temperature controlled items

Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.

How do I cancel or return an order?

Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.

To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.

*For full details on returns, see our terms and conditions page.

Reviews (73)

Q & A

Below are some recent questions we've received regarding Masivet Tablets for Dogs, including answers from our team.

1 June 2018 at 12:06am

MASIVET

DR RENNIE SHOOP

CAN YOU TREAT AN 8.3# DOG WITH MASIVET

  • Veterinary Advisor

Masivet must not be used in dogs less than six months of age or less than 4kg in weight. The dose rate is 12.5mg/kg once daily.

15 April 2016 at 8:55pm

Masitinib

Cheryl Woodring

  • VioVet customer since 2016
  • From: Washington, United States

Is this a generic drug for masitinib? I sent in a prescription and just want to make sure I'm paying for the correct one. I need the 150 mg not the 50 mg.

  • Non-Executive Director

The only brand name mastinib is sold under in the UK is Masivet. This is the original brand and not a generic. Other brand names can be chosen by the manufacturer when marketing it in other countries, but the product is the same. If your vet has prescribed mastinib, then Masivet is correct for you.